Health FDA Clears Ravulizumab for Neuromyelitis Optica Posted on March 26, 2024 by miyuru The United States Food and Drug Administration (FDA) has actually broadened the sign for the long-acting C5 enhance inhibitor, ravulizumab (Ultomiris, Alexion), to consist of grownups with anti– aquaporin-4 (AQP4)….